XML 31 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements
9 Months Ended
Sep. 28, 2018
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS
The classification of our financial assets within the fair value hierarchy that were measured and recorded at fair value on a recurring basis was as follows; the amounts presented exclude cash, but include investments classified as cash equivalents (in thousands):
 
September 30, 2018
 
Level 1
 
Level 2
 
Total
Money market funds
$
62,325

 
$

 
$
62,325

Certificates of deposit

 
19,098

 
19,098

Commercial paper

 
355,720

 
355,720

Corporate bonds

 
261,594

 
261,594

U.S. Treasury and government sponsored enterprises

 
50,564

 
50,564

Total financial assets
$
62,325

 
$
686,976

 
$
749,301

 
December 31, 2017
 
Level 1
 
Level 2
 
Total
Money market funds
$
45,478

 
$

 
$
45,478

Commercial paper

 
199,647

 
199,647

Corporate bonds

 
179,022

 
179,022

U.S. Treasury and government sponsored enterprises

 
16,263

 
16,263

Total financial assets
$
45,478

 
$
394,932

 
$
440,410


We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of those dates. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of September 30, 2018 or December 31, 2017 and there were no transfers of financial assets or liabilities classified as Level 3 during the nine months ended September 30, 2018 or 2017.
When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.
Our remaining financial assets and liabilities include Cash, Trade and other receivables, Unbilled collaboration revenue, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued collaboration liabilities, Rebates and fees due to customers, and other current and long-term liabilities. Those financial assets and liabilities are carried at cost which approximates their fair values.